Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL)

Summary: Treatment options for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) after failure of platinum-based therapy are limited. In this phase 2 trial, 40 patients with RM-NPC who failed platinum-based chemotherapy receive toripalimab plus anlotinib regimen. The objective...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yuchen Zhang, Qihua Zou, Baitian Zhao, Ning Su, Zhihua Li, Xicheng Wang, Panpan Liu, Xiaopeng Tian, Xiaojie Fang, Jun Cai, Lirong Li, Yingxian Liu, Yi Xia, Qingqing Cai
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2024-12-01
Reeks:	Cell Reports Medicine
Onderwerpen:	nasopharyngeal carcinoma recurrent or metastatic toripalimab anlotinib circulating tumor DNA clinical trial
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2666379124006049
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!